Physician profile
Brian K Abner
NPI 1275883050
$2,656.09
in general payments reported to CMS, 2019-2025
27 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $869 · 2022: $938 · 2023: $435 · 2024: $174 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $849.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $586.27 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Abbvie INC. | $295.42 | 2021-2025 | Vraylar, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $195.26 | 2022-2025 | |
| Novo Nordisk INC | $180.90 | 2021-2025 | Rybelsus, Ozempic |
| Biohaven Pharmaceutical Holding Company LTD. | $173.29 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $154.00 | 2021 | |
| Sunovion Pharmaceuticals INC. | $148.07 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $120.08 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.59 | 2023-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $78.52 | 2021-2023 | Breztri, Farxiga |
| Alexion Pharmaceuticals, INC. | $73.29 | 2021-2022 | |
| Pfizer INC. | $68.63 | 2022-2025 | |
| Abbott Laboratories | $58.57 | 2021-2022 | |
| Amgen INC. | $56.99 | 2022-2023 | Otezla, Repatha |
| Amarin Pharma, INC. | $54.85 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $54.24 | 2021-2023 | Shingrix, Arexvy |
| Astellas Pharma US INC | $51.11 | 2021 | |
| Ardelyx, INC. | $42.71 | 2023-2024 | Ibsrela |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.04 | 2025 | Caplyta |
| Insulet Corporation | $32.60 | 2021 | |
| Alnylam Pharmaceuticals INC. | $20.77 | 2025 | Givlaari |
| Alkermes, INC. | $20.11 | 2022 | |
| Hologic Sales and Service, LLC | $17.71 | 2023 | Aptima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.77 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.23 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.05 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $13.02 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Abner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.